GuruFocus.com16h agobearish
Eli Lilly Stock Falls While Retatrutide Lawsuits ExpandLilly is trying to protect an experimental obesity medicine from unauthorized sellers before regulators decide whether to approve it.
Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
326last 24h
2138last 7d
379● bullish (7d)
188● bearish (7d)
204publishers
Stocktwits21h agobearish
Eli Lilly Steps Up Retatrutide Crackdown With Six New Lawsuits – CMO Hyman Says Drug Sold In Black Market Is ‘Not A Medicine’Lilly said the products being sold on the black market are unverified, unapproved, and not worth the risk.
BioPharma Dive22h agobearish
Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutideAhead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine.
Motley Fool22d agobearish
"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means for Both Stocks.Novo Nordisk is also demanding that Eli Lilly pull its ads and pay damages.
Stocktwits22d agobearish
Novo Nordisk Lawsuit Against Eli Lilly: Wegovy Maker Alleges Misleading Zepbound, Mounjaro AdsNovo alleges that Lilly’s Zepbound advertisements compare the drug’s highest approved dose with lower doses of Wegovy.
Reuters43d agobearish
Exclusive-US House committee opens investigation into Merck, AbbVie China drug trialsJune 30 (Reuters) - A bipartisan group of U. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved in clinical trials conducted in China that helped fuel the communist country's military capability, according to letters seen by Reuters.